Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment tags : Trial save search
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.46 -1.21% -1.22% 21K
|
Health Technology
|
| O: 4.43%
H: 0.0%
C: 0.0%
dm199 first stroke treatment for trial therapeutics
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Published: 2024-04-17 (Crawled : 12:00) - prnewswire.com
NRBO | $3.325 -3.34% -3.46% 21K
|
Health Technology
|
| O: 8.53%
H: 0.0%
C: -6.23%
da-1726 obesity first treatment pharmaceuticals for trial
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea & Vomiting at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
EGRX | $4.63 3.35% 3.24% 60K
|
Health Technology
|
| O: -8.14%
H: 19.55%
C: 18.18%
conference treatment pharmaceuticals for trial response
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
EGRX | $4.63 3.35% 3.24% 60K
|
Health Technology
|
| O: -8.14%
H: 19.55%
C: 18.18%
conference treatment pharmaceuticals for trial response
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.7477 -7.18% -7.73% 1.7M
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
ADIL | $1.9 -12.44% -14.21% 310K
|
Health Technology
|
| O: 123.48%
H: 0.0%
C: 0.0%
ad04 alcohol publication treatment pharmaceuticals for trial potential
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: 0.57%
H: 11.65%
C: 4.55%
disease control treatment trial therapeutics
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Published: 2024-04-08 (Crawled : 12:30) - prnewswire.com
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 0.57%
H: 7.01%
C: 3.79%
nrx-101 depression treatment pharmaceuticals trial
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS | $11.78 0.0% 69K
|
n/a
|
| O: 0.36%
H: 0.18%
C: -2.76%
ocs-01 positive treatment for meeting trial results
SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women
Published: 2024-04-07 (Crawled : 16:20) - prnewswire.com
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
| Email alert
Add to watchlist
EW | $85.94 -0.59% 0.0% 3.9M
|
Health Technology
| Email alert
Add to watchlist
treatment for women smart trial platform
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
Published: 2024-04-04 (Crawled : 23:00) - biospace.com/
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: -2.33%
H: 1.64%
C: -4.91%
ecur-506 fda drug treatment clearance for application trial
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.24%
H: 0.08%
C: -2.42%
mk-1084 keytruda lung merck cancer cell treatment trial
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
vx-147 disease kidney treatment trial
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Published: 2024-04-01 (Crawled : 12:00) - prnewswire.com
NRBO | $3.325 -3.34% -3.46% 21K
|
Health Technology
|
| O: -1.2%
H: 0.0%
C: -1.46%
da-1241 treatment pharmaceuticals trial
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: -3.52%
treatment trial therapeutics solriamfetol
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
APGE | $46.98 -2.83% -2.92% 470K
|
|
| O: 0.6%
H: 2.5%
C: -5.58%
apg808 first disease antibody treatment trial therapeutics
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
Published: 2024-03-20 (Crawled : 12:00) - globenewswire.com
FEMY | $1.33 1.53% 1.5% 160K
|
Manufacturing
|
| O: -6.5%
H: 0.53%
C: -3.74%
femaseed positive treatment topline trial
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.33%
H: 1.02%
C: 0.48%
opdivo treatment trial advanced plus
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 0.84%
H: 5.95%
C: 5.09%
treatment trial therapeutics solriamfetol
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Published: 2024-03-13 (Crawled : 12:00) - prnewswire.com
NRBO | $3.325 -3.34% -3.46% 21K
|
Health Technology
|
| O: 3.49%
H: 0.2%
C: -11.31%
da-1241 approval review treatment pharmaceuticals trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.